logo
Fetus of brain dead Georgia woman kept alive due to abortion ban is growing, says family

Fetus of brain dead Georgia woman kept alive due to abortion ban is growing, says family

The Guardian20-05-2025
The fetus of a brain dead Georgia woman who is being kept alive to carry out her pregnancy is continuing to grow, the woman's mother said late Monday, days after the controversial case exploded into the national news and sparked questions about the ethics of using the state's anti-abortion law to keep a woman with no chance of recovery on life support.
'He has his toes, arms, limbs – everything is forming,' the mother, April Newkirk, told the local news station 11Alive. 'We're just hoping he makes it.'
The Georgia woman, Adriana Smith, went to a hospital in February with what she thought was an intense headache, Newkirk, told 11 Alive, which first reported the story. At the time, Smith was about eight weeks into her pregnancy.
The hospital released Smith after providing her with medication, Newkirk said. The next day, Smith was rushed back to the hospital after she woke up gasping for air. The hospital diagnosed her with blood clots in her brain. Within hours of her first visit, she was declared braindead.
Under Georgia law, abortion is banned after about six weeks of pregnancy. That ban also contains provisions that strengthen the concept of 'fetal personhood', a doctrine that holds that embryos and fetuses should be considered people – and, as such, are entitled to full legal rights and protections. Newkirk said doctors told the family the law requires keeping her alive to preserve the pregnancy.
'We didn't have a choice or a say about it,' Newkirk said. 'We want the baby. That's a part of my daughter. But the decision should have been left to us – not the state.'
Smith is currently about 22 weeks into her pregnancy. The hospital plans to keep Smith on life support until early August, when doctors will deliver the baby through a caesarean section, 11Alive reported.
'The chances of there being a healthy newborn at the end of this is very, very small,' Steven Ralston, the director of the maternal fetal medicine division at George Washington University, told the Washington Post. Newkirk said last week that the baby has fluid in the brain. 'He may be blind, may not be able to walk, may not survive once he's born,' she said.
The family has named the baby Chance, Newkirk said.
'Right now, the journey is for baby Chance to survive,' Newkirk said on Monday. 'Whatever condition God allows him to come here in, we're going to love him just the same.'
Smith's case has sparked a nationwide debate about medical consent and the potentially sweeping reach of anti-abortion laws. Abortion rights activists have spent years warning about these laws' unforeseen consequences, as instituting fetal personhood can lead to the rights of a pregnant person being pitted against that of the fetus inside them. In the years since Roe v Wade's 2022 overturning, dozens of pregnant women have said that abortion bans led them to be denied abortions even in medical emergencies.
The hospital where Smith is currently located has not commented on her case, citing privacy laws. However, it said in a statement that it 'uses consensus from clinical experts, medical literature, and legal guidance to support our providers as they make individualized treatment recommendations in compliance with Georgia's abortion laws and all other applicable laws'.
The office of Georgia's attorney general, Chris Carr, has released a statement declaring that Georgia's six-week law does not require medical professionals to keep women alive on life support after being declared brain dead. 'Removing life support is not an action with the purpose to terminate a pregnancy,' Carr's spokesperson, Kara Murray, said in the statement.
Some anti-abortion advocates, however, have taken the opposite view. Georgia state Sen. Ed Setzler, who sponsored the state's abortion ban, told the Associated Press that 'it is completely appropriate that the hospital do what they can to save the life of the child'.
He continued: 'I think this is an unusual circumstance, but I think it highlights the value of innocent human life. I think the hospital is acting appropriately.'
Students for Life of America, a powerful national anti-abortion group, has also backed the decision to keep Smith on life support.
'While Adriana can no longer speak for herself, her son's life still matters. Her doctors are doing the right thing by treating him as a unique patient,' the organization said in a statement, which was accompanied by a fundraiser for Smith's family.
Smith's family has their own fundraiser to help cover costs associated with her care and the possibilities that her son will be born with disabilities.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pfizer CEO says pharmaceutical companies want to work with Trump to make medicine more affordable
Pfizer CEO says pharmaceutical companies want to work with Trump to make medicine more affordable

The Independent

time22 minutes ago

  • The Independent

Pfizer CEO says pharmaceutical companies want to work with Trump to make medicine more affordable

Pfizer CEO Albert Bourla announced that major pharmaceutical companies are ready to work with the Trump administration to make medicines more affordable and directly available to consumers. This move comes after Trump demanded that 17 drugmakers expand direct-to-consumer options and lower prices to match those in other industrialized countries, threatening to use 'every tool' if they did not comply. Pfizer and Bristol Myers Squibb have already revealed plans to offer their blood thinner Eliquis at a lower price online, building on Pfizer's existing direct-to-consumer telehealth and prescription services. Other companies, such as Eli Lilly and Novo Nordisk, are also exploring direct access for their obesity drugs, aiming to bypass pharmacy benefit managers. Despite potential sector-specific tariffs on pharmaceutical imports, which could escalate to 250 percent, Pfizer expects to meet its financial forecasts, though experts have refuted Trump's claims of significant drug price reductions.

US FDA approves Teva's Ajovy for migraine prevention in children
US FDA approves Teva's Ajovy for migraine prevention in children

Reuters

time23 minutes ago

  • Reuters

US FDA approves Teva's Ajovy for migraine prevention in children

Aug 5 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva Pharma ( opens new tab, to help prevent migraines in children aged six and older who weigh 45 kilograms or more. This is the first time a drug has been approved for preventing migraines in children. The injection is given once a month. The most common side effects are pain and redness where the shot is given. Serious side effects include itchiness, rash and drug hypersensitivity, but the overall safety was similar to what was seen in adult migraine studies, the FDA said. Episodic migraine refers to recurring severe headaches in children that do not occur daily but are frequent enough to interfere with daily activities. These headaches are often accompanied by symptoms such as nausea, fatigue and sensitivity to light and sound. Ajovy is part of a class of drugs called CGRP inhibitors, which block a protein involved in triggering migraines. The treatment was first approved for adults in 2018 and competes with similar drugs such as Amgen's (AMGN.O), opens new tab Aimovig and Eli Lilly's (LLY.N), opens new tab Emgality.

US health agency to wind down mRNA vaccine development
US health agency to wind down mRNA vaccine development

Reuters

time23 minutes ago

  • Reuters

US health agency to wind down mRNA vaccine development

Aug 5 (Reuters) - The U.S. Department of Health and Human Services said on Tuesday it would wind down mRNA vaccine development activities under its biomedical research unit. The unit, Biomedical Advanced Research and Development Authority, helps companies develop medical supplies to address public health threats, and had also provided billions of dollars for development of COVID-19 vaccines during the pandemic. HHS said the wind down includes cancellation of a contract awarded to Moderna (MRNA.O), opens new tab for the late-stage development of its bird flu vaccine for humans and the right to purchase the shots, a move first reported in May. The U.S. health agency said it is also rejecting or canceling multiple pre-award solicitations, including proposals from Pfizer (PFE.N), opens new tab, Sanofi Pasteur ( opens new tab, CSL Seqirus ( opens new tab, Gritstone and others. In total, this affects 22 projects worth nearly $500 million, the agency said. HHS said the decision follows a comprehensive review of mRNA-related investments initiated during the COVID-19 public health emergency.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store